Economics and the new generation of targeted therapies for non-small cell lung cancer

Journal of the National Cancer Institute

Volumn 102, Issue 5, 2010, Pages 287-288

  Ramsey, Scott D ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PLATINUM DERIVATIVE;

CANCER CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDICATION; EDITORIAL; GENOME ANALYSIS; HUMAN; LUNG NON SMALL CELL CANCER; PHARMACOGENOMICS; PRIORITY JOURNAL; UNITED STATES;

ANGIOGENESIS INHIBITORS; CANADA; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES;

EID: 77749292143     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq012     Document Type: Editorial

References (4)

1. Bradbury PA, Tu D, Seymour L, et al. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. J Natl Cancer Inst. 2010;102(5):298-306.
2. Gross S. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8(2):165-178.
3. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46(4):349-356.
4. Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist. 2006;11(2):90-95.